January 2, 2024 - SDN Chronicle

Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity

ROCKVILLE, Md. and SUZHOU, China, Jan. 2, 2024 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801),…